Xenon Pharmaceuticals Stock (NASDAQ: XENE)

Xenon Pharmaceuticals (NASDAQ:XENE) Stock

Xenon Pharmaceuticals

Xenon Pharmaceuticals Inc is a clinical-stage biopharmaceutical company committed to developing therapeutics to improve the lives of patients with neurological disorders, including rare central nervous system, or CNS, conditions. The product candidates of the group include XEN1101, XEN901, and XEN496 for Epilepsy, and Nav1.7 oral inhibitors for Pain. Geographically the activities are carried out throughout Canada.

laboratory-563423_1920

Analyst Color

Biotech

Equities

News

Health Care

Price Target

Initiation

Analyst Ratings

Trading Ideas

General

BHVN

CERE

KRTX

XENE

Biohaven&#39;s potential with RBC Capital Markets&#39; optimistic outlook.. RBC sees blockbuster potential of $3.2 billion across epilepsy and mood disorders. Anticipate significant developments in lead asset Kv7-7000&#39;s Phase 3 trial this year, reducing late-stage risks.

This Analyst Is Bullish On Biohaven&#39;s Approach in Neuro-Psych Space

Xenon Pharmaceuticals Inc (NASDAQ: XENE) shares are trading higher by 7.8% to $36.38 Thursday afternoon. The company announced the pricing of its upsized $300 million public offering of 8,461,542 common shares at 

Why Xenon Pharmaceuticals Stock (XENE) Is Seeing Blue Skies Today

Penny Stocks

Small Cap

Markets

AFRM

CHPT

CROX

LASR

SHOP

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.

Boeing To Rally More Than 25%? Here Are 10 Top Analyst Forecasts For Tuesday

Xenon Pharmaceuticals Inc. - Common Shares

Xenon Pharmaceuticals Inc

Xenetic Biosciences Inc

Xenetic Biosciences Inc Warrants (19/07/2024)

Deutsche Bank analyst David Hoang initiates coverage on Xenon Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XENE#NASDAQ">XENE</a>) with a Buy rating and announces Price Target of $67.

Deutsche Bank Initiates Coverage On Xenon Pharmaceuticals with Buy Rating, Announces Price Target of $67

HC Wainwright &amp; Co. analyst Douglas Tsao reiterates Xenon Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XENE#NASDAQ">XENE</a>) with a Buy and maintains $53 price target.

Reiteration

HC Wainwright & Co. Reiterates Buy on Xenon Pharmaceuticals, Maintains $53 Price Target

– OLE data shows sustained monthly reduction in seizure frequency, impressive seizure freedom rates, and consistent AE safety profile suggesting long-term efficacy and tolerability of azetukalner
– Approximately one in three patients on drug for at least 36 months achieved seizure freedom for a period of one year or longer
– Sustained monthly reductions in seizure frequency maintained at 85% at OLE study month 36
– Patient-reported survey data and literature review illustrate significant mental health and comorbidity burdens of focal onset seizures highlighting areas of unmet need for people living with epilepsy
– New pre-clinical data shows Nav1.1 potentiator provides protection against spontaneous seizures and SUDEP in pre-clinical Dravet model

Xenon New Long-Term Azetukalner Data Shows Sustained Monthly Reductions In Seizure Frequency Maintained At 85% At OLE Study Month 36; Approximately 1/3 Patients On Drug For At Least 36-Months Achieved Seizure Freedom For A Period Of 1-Year Or Longer

– OLE data shows sustained monthly reduction in seizure frequency, impressive seizure freedom rates, and consistent AE safety profile suggesting long-term efficacy and tolerability of azetukalner– Approximately one in
– OLE data shows sustained monthly reduction in seizure frequency, impressive seizure freedom rates, and consistent AE safety profile suggesting long-term efficacy and tolerability of azetukalner
– Approximately one in three patients on drug for at least 36 months achieved seizure freedom for a period of one year or longer
– Sustained monthly reductions in seizure frequency maintained at 85% at OLE study month 36
– Patient-reported survey data and literature review illustrate significant mental health and comorbidity burdens of focal onset seizures highlighting areas of unmet need for people living with epilepsy
– New pre-clinical data shows Nav1.1 potentiator provides protection against spontaneous seizures and SUDEP in pre-clinical Dravet model

Xenon Announces New Long-Term Azetukalner Data From X-TOLE OLE Study In FOS At AES 2024

<ul>
<li>Five posters to be presented including new long-term 36-month data from the ongoing X-TOLE OLE study of azetukalner in FOS and findings around mental health and comorbidity burdens of FOS
<ul>
<li>New pre-clinical data from the Company's Nav1.1 program</li>
</ul>
</li>
</ul>

Events

Xenon To Present Long-Term Azetukalner Data At AES 2024

Needham analyst Serge Belanger reiterates Xenon Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XENE#NASDAQ">XENE</a>) with a Buy and maintains $60 price target.

Needham Reiterates Buy on Xenon Pharmaceuticals, Maintains $60 Price Target

Xenon Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XENE#NASDAQ">XENE</a>) reported quarterly losses of $(0.81) per share which met the analyst consensus estimate.

Earnings

Xenon Pharmaceuticals Q3 2024 GAAP EPS $(0.81), Inline

ABOS

ABSI

ACNT

ACTG

AENT

AGEN

AIOT

AIRG

ALIT

ALTG

AMBC

AMPS

AMTX

APEI

AREB

ARIS

ARMN

ATRA

AUTL

Avadel Pharmaceuticals plc - American Depositary Shares each representing one Ordinary Share

AVDL

AXSM

AZTA

BHIL

BLDE

BLFS

BLTE

The Beachbody Company, Inc. Class A Common Stock

BODI

BRTX

BTMD

BTTR

BWAY

BXSL

BZFD

CAMT

CART

CATX

CAVA

CBAT

CBLL

CCLD

CGEN

CHGG

CHMI

CLSD

CNNE

CRNX

CRON

CRVS

CRWS

CVAC

CXAI

DAVA

DAVE

DRCT

DYAI

EARN

EGAN

ELMD

ETON

EVCM

EVGO

EYEN

FENG

FGEN

FIHL

FLNG

FOUR

FTCI

GENI

GENK

GMGI

GOVX

GRAL

GRDN

GROV

GRPN

GRVY

Earnings Scheduled For November 12, 2024

Xenon Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XENE#NASDAQ">XENE</a>) is set to give its latest quarterly earnings report on Tuesday, 2024-11-12. Here's what investors need to know before the announcement.
Analysts estimate that Xenon Pharmaceuticals will report an earnings per share (EPS) of $-0.83. 
The market awaits Xenon Pharmaceuticals's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.
It's important for new investors to understand that guidance can be a significant driver of stock prices.
<h3>Performance in Previous Earnings</h3>
During the last quarter, the company reported an EPS missed by $0.05, leading to a 3.19% drop in the share price on the subsequent day.
Here's a look at Xenon Pharmaceuticals's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
<th>Q3 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.70</td>
<td>-0.66</td>
<td>-0.76</td>
<td>-0.77</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.75</td>
<td>-0.62</td>
<td>-0.64</td>
<td>-0.73</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-3.0%</td>
<td>-5.0%</td>
<td>-1.0%</td>
<td>-7.000000000000001%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2024/1731333676_0.png" alt="eps graph" />
<h3>Market Performance of Xenon Pharmaceuticals's Stock</h3>
Shares of Xenon Pharmaceuticals were trading at $45.0 as of November 07. Over the last 52-week period, shares are up 51.26%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. 
<a href="https://www.benzinga.com/quote/XENE/earnings">To track all earnings releases for Xenon Pharmaceuticals visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings Preview: Xenon Pharmaceuticals

Raymond James analyst Danielle Brill reinstates Xenon Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XENE#NASDAQ">XENE</a>) with a Outperform and announces $50 price target.

Raymond James Reinstates Outperform on Xenon Pharmaceuticals, Announces $50 Price Target

HC Wainwright &amp; Co. analyst Douglas Tsao initiates coverage on Xenon Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XENE#NASDAQ">XENE</a>) with a Buy rating and announces Price Target of $53.

HC Wainwright & Co. Initiates Coverage On Xenon Pharmaceuticals with Buy Rating, Announces Price Target of $53

RBC Capital analyst Brian Abrahams reiterates Xenon Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XENE#NASDAQ">XENE</a>) with a Outperform and maintains $55 price target.

RBC Capital Reiterates Outperform on Xenon Pharmaceuticals, Maintains $55 Price Target

Xenon Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XENE#NASDAQ">XENE</a>), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in need, today announced the appointment of Matthew D. Ronsheim, Ph.D. as Chief Operating Officer and a member of the Xenon senior executive team. In this new role, Dr. Ronsheim will lead Chemistry, Manufacturing and Controls (CMC), Program Management and Quality Assurance and as a member of the senior executive team will be responsible for providing strategic and operational leadership for the Company's pipeline of small molecule programs with a focus on preparation for the commercial launch of azetukalner.

Management

Xenon Expands Leadership Team With Matthew D. Ronsheim as Chief Operating Officer

Needham analyst Serge Belanger maintains Xenon Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XENE#NASDAQ">XENE</a>) with a Buy and lowers the price target from $62 to $60.

Needham Maintains Buy on Xenon Pharmaceuticals, Lowers Price Target to $60

Cantor Fitzgerald analyst Josh Schimmer reiterates Xenon Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XENE#NASDAQ">XENE</a>) with a Overweight and maintains $65 price target.

Cantor Fitzgerald Reiterates Overweight on Xenon Pharmaceuticals, Maintains $65 Price Target

Wedbush analyst Laura Chico maintains Xenon Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XENE#NASDAQ">XENE</a>) with a Outperform and lowers the price target from $50 to $49.

Wedbush Maintains Outperform on Xenon Pharmaceuticals, Lowers Price Target to $49

Xenon Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XENE#NASDAQ">XENE</a>) reported quarterly losses of $(0.75) per share which missed the analyst consensus estimate of $(0.70) by 7.14 percent.

Earnings Misses

Xenon Pharmaceuticals Q2 2024 GAAP EPS $(0.75) Misses $(0.70) Estimate

Xenon Pharmaceuticals Presents Phase 2 X-NOVA Clinical Trial Data Of Azetukalner in Major Depressive Disorder At ASCP 2024 Annual Meeting

Press Releases

Xenon Showcases Azetukalner Data at 15th European Epilepsy Congress

Xenon to Present at BofA Securities 2024 CNS Therapeutics Virtual Conference

Xenon to Report Q3 2024 Financial Results on November 12, 2024

Xenon Reports Q3 2024 Financial Results and Business Update

Xenon to Present at Upcoming Investor Conferences

Xenon to Showcase New Long-Term Azetukalner Data at AES 2024

Xenon Showcases New Long-Term Azetukalner Data from X-TOLE OLE Study in FOS at AES 2024

Comments

Xenon Pharmaceuticals

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga